Beijing Tsinghua Changgung Hospital

Beijing, Beijing Municipality 102218

5 studies enrolling now · 8 studies all time

What they study most

Acute Ischemic Stroke, Advanced Liver Cancer, Advanced or Metastatic MTAP-deleted Solid Tumors, Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease, Receiving Dialysis, Dialysis, ESRD (End-Stage Renal Disease), Hyperphosphatemia, Immunoglobulin A Nephropathy (IgAN), Obesity, Overweight, Primary Membranous Nephropathy

Studies at this site

• A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) — Recruiting now
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity — Recruiting now
• A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) — Recruiting now
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor — Recruiting now
• A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China — Recruiting now
• A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke — Completed
• A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer — Running, not enrolling
• An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors — Stopped early